<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: gain approval", fill: "#b0e0e6"},
{source: "3: gain approval", target: "3: commercialize", fill: "#b0e0e6"},
{source: "3: commercialize", target: "3: product candidates", fill: "#b0e0e6"},
{source: "3: gain approval", target: "4: foreseeable future", fill: "#b784a7"},
{source: "4: foreseeable future", target: "4: profitability will", fill: "#b784a7"},
{source: "4: profitability will", target: "4: dependent on", fill: "#b784a7"},
{source: "4: dependent on", target: "4: successful development approval", fill: "#b784a7"},
{source: "4: successful development approval", target: "4: commercialization", fill: "#b784a7"},
{source: "4: commercialization", target: "4: current product candidates", fill: "#b784a7"},
{source: "4: foreseeable future", target: "5: regulatory approval", fill: "#0073cf"},
{source: "5: regulatory approval", target: "5: factors could negatively", fill: "#0073cf"},
{source: "5: factors could negatively", target: "5: commercialize", fill: "#0073cf"},
{source: "5: commercialize", target: "5: risk factors", fill: "#0073cf"},
{source: "5: risk factors", target: "5: follow as", fill: "#0073cf"},
{source: "5: follow as", target: "5: well as negative inconclusive", fill: "#0073cf"},
{source: "5: well as negative inconclusive", target: "5: otherwise unfavorable", fill: "#0073cf"},
{source: "5: otherwise unfavorable", target: "5: clinical trials such as", fill: "#0073cf"},
{source: "5: clinical trials such as", target: "5: with respect", fill: "#0073cf"},
{source: "5: with respect", target: "5: discontinue development", fill: "#0073cf"},
{source: "5: regulatory approval", target: "19: regulatory", fill: "#ace1af"},
{source: "19: regulatory", target: "19: requirements", fill: "#ace1af"},
{source: "19: requirements", target: "19: regulatory environment during", fill: "#ace1af"},
{source: "19: regulatory environment during", target: "19: development", fill: "#ace1af"},
{source: "19: development", target: "19: product candidates", fill: "#ace1af"},
{source: "19: product candidates", target: "19: application", fill: "#ace1af"},
{source: "19: regulatory", target: "21: drug development", fill: "#c19a6b"},
{source: "21: drug development", target: "21: regulatory approval", fill: "#c19a6b"},
{source: "21: regulatory approval", target: "21: candidates", fill: "#c19a6b"},
{source: "21: candidates", target: "21: years during which", fill: "#c19a6b"},
{source: "21: years during which", target: "21: interpretations", fill: "#c19a6b"},
{source: "21: interpretations", target: "21: standards against which drugs", fill: "#c19a6b"},
{source: "21: standards against which drugs", target: "21: approval may evolve", fill: "#c19a6b"},
{source: "21: drug development", target: "36: collaborators may", fill: "#cf1020"},
{source: "36: collaborators may", target: "36: agreements", fill: "#cf1020"},
{source: "36: agreements", target: "36: pay termination payments under", fill: "#cf1020"},
{source: "36: collaborators may", target: "46: example under", fill: "#df00ff"},
{source: "46: example under", target: "46: current collaboration agreement", fill: "#df00ff"},
{source: "46: current collaboration agreement", target: "46: Valeant NA ", fill: "#df00ff"},
{source: "46: Valeant NA ", target: "46: additional studies", fill: "#df00ff"},
{source: "46: additional studies", target: "46: of the NDA ", fill: "#df00ff"},
{source: "46: of the NDA ", target: "46: would jeopardize", fill: "#df00ff"},
{source: "46: would jeopardize", target: "46: commercial viability", fill: "#df00ff"},
{source: "46: commercial viability", target: "46: financial resources available", fill: "#df00ff"},
{source: "46: example under", target: "47: agreement", fill: "#ffdb58"},
{source: "47: agreement", target: "47: to Valeant NA ", fill: "#ffdb58"},
{source: "47: agreement", target: "START_HERE", fill: "#ffdb58"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of whom 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paris_Agreement">Paris Agreement</a></td>
      <td>The Paris Agreement (French: Accord de Paris), often referred to as the Paris Accords or the Paris Climate Accords, is an international treaty on climate change, adopted in 2015. It covers climate change mitigation, adaptation, and finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Munich_Agreement">Munich Agreement</a></td>
      <td>The Munich Agreement (Czech: Mnichovská dohoda; Slovak: Mníchovská dohoda; German: Münchner Abkommen) was an agreement concluded at Munich on 30 September 1938, by Germany, the United Kingdom, France, and Italy. It provided "cession to Germany of the Sudeten German territory" of Czechoslovakia, despite the existence of a 1924 alliance agreement and 1925 military pact between France and the Czechoslovak Republic, for which it is also known as the Munich Betrayal (Mnichovská zrada; Mníchovská zrada).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Haavara_Agreement">Haavara Agreement</a></td>
      <td>The Haavara Agreement (Hebrew: הֶסְכֵּם הַעֲבָרָה‎  Translit.: heskem haavara   Translated: "transfer agreement") was an agreement between Nazi Germany and Zionist German Jews signed on 25 August 1933. The agreement was finalized after three months of talks by the Zionist Federation of Germany, the Anglo-Palestine Bank (under the directive of the Jewish Agency) and the economic authorities of Nazi Germany.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Simla_Agreement">Simla Agreement</a></td>
      <td>The Simla Agreement, also spelled Shimla Agreement, was a peace treaty signed between India and Pakistan on 2 July 1972 in Shimla, the capital city of the Indian state of Himachal Pradesh. It followed the Indo-Pakistani War of 1971, which began after India intervened in East Pakistan as an ally of Bengali rebels who were fighting against Pakistani state forces in the Bangladesh Liberation War.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>POZEN INC /NC      Item 1A Risk Factors        Our business is subject to <font color="blue">certain risks</font> and uncertainties, each of which     <font color="blue">could materially <font color="blue">adversely affect</font></font> our business, financial condition, cash     flows and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business        We <font color="blue">depend heavily on</font> the success of our <font color="blue">product <font color="blue">candidates</font></font>, which may never     be approved for <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>If we are unable to develop, <font color="blue">gain approval</font>     of or <font color="blue">commercialize</font> those <font color="blue">product <font color="blue">candidates</font></font>, we will never receive revenues     from the sale of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We  anticipate  that for the <font color="blue">foreseeable future</font> our ability to achieve     <font color="blue"><font color="blue">profitability</font> will</font> be <font color="blue">dependent on</font> the successful <font color="blue">development</font>, approval and     <font color="blue">commercialization</font> of our current <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition to the     <font color="blue">inability</font> to obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, many other <font color="blue">factors could negatively</font>     affect the success of our efforts to develop and <font color="blue">commercialize</font> our product     <font color="blue">candidates</font>, including those discussed in the <font color="blue">risk factors</font> that <font color="blue">follow as</font>     well as negative, inconclusive or <font color="blue">otherwise unfavorable</font> results from any     studies or <font color="blue"><font color="blue">clinical trial</font>s</font>, such as those that we obtained <font color="blue">with respect</font> to     MT 500, which led to our decision to <font color="blue"><font color="blue">discontinue</font> <font color="blue">development</font></font> of that product     candidate in 2002</td>
    </tr>
    <tr>
      <td>We have also decided to <font color="blue"><font color="blue">discontinue</font> <font color="blue">development</font></font> of MT 100     <font color="blue">in the US </font>and to explore the <font color="blue">possibility</font> of selling or <font color="blue">otherwise disposing</font>     of  the  MT 100 asset, <font color="blue">based upon</font> the <font color="blue">de<font color="blue">termination</font></font> of an FDA Advisory     Committee in August 2005</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA Advisory Committee </font>determined, following     our receipt of a not <font color="blue"><font color="blue">approvable letter</font> from</font> the FDA in 2004 for our NDA for     MT 100, that the potential, but unquantified, risk of <font color="blue">tardive dyskinesia</font>, an     <font color="blue">involuntary movement disorder <font color="blue">associated with</font></font> the use of <font color="blue">metoclopramide</font>, one     of the <font color="blue">components</font> of MT 100, outweighed the benefits, as defined by the FDA,     of  <font color="blue">metoclopramide</font>  <font color="blue">hydrochloride</font> in <font color="blue">combination</font> with naproxen sodium</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">based upon</font> our <font color="blue">understandings from</font> our <font color="blue">recent communications with</font>     the FDA, in which the FDA restated its concerns that approval of MT 300 was     <font color="blue">problematic due</font> to the <font color="blue">higher incidence</font> of <font color="blue">nausea at two hours following</font>     dosing in <font color="blue">patients treated with</font> MT 300 compared with placebo, we do not     believe it is possible to reverse the not <font color="blue">approvable status</font> of MT 300 stated     in the not <font color="blue">approvable letter</font> we received from the FDA in 2003</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">incurred losses</font> since inception</font> and we <font color="blue">may continue</font> to <font color="blue">incur losses</font>     for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We do not have a <font color="blue">current source</font> of product     revenue</td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred losses</font> in <font color="blue">each year since</font> our inception</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31,     2005, we had an <font color="blue">accumulated deficit</font> of approximately dlra112dtta5 million</td>
    </tr>
    <tr>
      <td>Our     ability to receive <font color="blue">product revenue from</font> the sale of products is <font color="blue">dependent on</font>     a number of factors, <font color="blue">principally</font> the <font color="blue">development</font>, <font color="blue"><font color="blue">regulatory</font> approval</font> and     successful <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We expect that the     amount of our operating <font color="blue">losses will fluctuate <font color="blue"><font color="blue">significant</font>ly</font> from quarter</font> to     quarter  <font color="blue">principally</font>  as  a  result  of increases and <font color="blue">decreases</font> in our     <font color="blue"><font color="blue">development</font> efforts</font> and the timing of payments that we may receive from     others</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur <font color="blue">significant</font></font> operating losses and do     not know when, if and to what extent we <font color="blue">will generate product revenue</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">only current potential sources</font> of revenue are the payments that we may     receive  pursuant to our <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font> with</font> GSK for Trexima</td>
    </tr>
    <tr>
      <td>Further, we may have to pay <font color="blue">Valeant NA </font>a dlra1dtta0 million <font color="blue">withdrawal fee</font> if we     do not prevail in our current dispute with them as to whether the withdrawal     fee  is  payable</td>
    </tr>
    <tr>
      <td>This amount is <font color="blue">currently reflected</font> in our financial     <font color="blue">statements as deferred revenue</font> and will never be recognized as revenue if     repaid</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>Changes  in  <font color="blue">regulatory</font>  approval  policy  or  statutory or <font color="blue">regulatory</font>     <font color="blue"><font color="blue">requirement</font>s</font>, or in the <font color="blue">regulatory</font> environment, during the <font color="blue">development</font>     period  of  any  of our <font color="blue">product <font color="blue">candidates</font></font> may result in delays in the     approval, or rejection, of the <font color="blue">application</font> for approval of one or more of     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we fail to obtain approval, or are delayed in     obtaining approval, of our <font color="blue">product <font color="blue">candidates</font></font>, our ability to generate     <font color="blue">revenue will</font> be <font color="blue">severely impaired</font></td>
    </tr>
    <tr>
      <td>The  process  of  drug <font color="blue">development</font> and <font color="blue"><font color="blue">regulatory</font> approval</font> for product     <font color="blue">candidates</font> takes many years, during which time the FDA’s <font color="blue"><font color="blue">interpretation</font>s</font> of     the <font color="blue">standards against which drugs</font> are judged for <font color="blue">approval may evolve</font> or     change</td>
    </tr>
    <tr>
      <td>The FDA can also change its <font color="blue">approval policies</font> <font color="blue">based upon</font> changes in     laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In addition, it can decide, <font color="blue">based on</font> its then current     <font color="blue">approval policies</font>, any changes in those policies and its <font color="blue">broad <font color="blue">discretion</font></font> in     the <font color="blue">approval process</font>, to weigh the benefits and the risks of <font color="blue">every drug</font>     candidate</td>
    </tr>
    <tr>
      <td>As a result of any of the foregoing, the FDA may decide that the     data we submit in support of an <font color="blue">application</font> for approval of a <font color="blue">drug candidate</font>     are insufficient for approval</td>
    </tr>
    <tr>
      <td>Further, changes in policy or <font color="blue">interpretation</font>     may  not  be  the subject of <font color="blue">published <font color="blue">guidelines</font></font> and <font color="blue">may therefore</font> be     <font color="blue">difficult</font> to evaluate</td>
    </tr>
    <tr>
      <td>For example, the FDA has not <font color="blue">recently published</font>     <font color="blue">guidelines</font> for the approval of <font color="blue">new <font color="blue">migraine therapies</font></font>, and we have had to     <font color="blue">rely on periodic guidance from</font> the FDA obtained in <font color="blue">conversations</font> and other     meetings, the content of which may be subject to <font color="blue"><font color="blue">significant</font> modification</font>     over the period of a drug’s <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td>There is also the risk that     we and the FDA <font color="blue">may interpret such guidance <font color="blue">different</font>ly</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">additional</font> information about the <font color="blue"><font color="blue">potential risk</font>s</font> of <font color="blue">marketed drugs</font>     may  affect the <font color="blue"><font color="blue">regulatory</font> approval</font> environment, or the FDA’s approval     policies, for new <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>For example, in <font color="blue">February </font>2005 an     advisory  committee  convened  by the FDA met to address the potential     <font color="blue">cardiovascular risks</font> of COX-2 selective NSAIDs and related drugs in response     to <font color="blue">disclosures</font> made about possible adverse effects from the use of some of     these  drugs</td>
    </tr>
    <tr>
      <td>On April 7, 2005 the FDA issued a Public Health Advisory     (Advisory)  based,  in  part, upon the <font color="blue">recommendations</font> of the advisory     committee</td>
    </tr>
    <tr>
      <td><font color="blue">The Advisory </font>stated that it would require that <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> of     all <font color="blue">prescription products containing</font> NSAIDs <font color="blue">provide warnings</font> regarding the     potential for adverse cardiovascular events as well as life-threatening     <font color="blue">gastrointestinal</font>  events  <font color="blue">associated with</font> the use of NSAIDs</td>
    </tr>
    <tr>
      <td>Moreover,     subsequent to the FDA <font color="blue">advisory committee meeting</font> in <font color="blue">February </font>2005, the FDA     has indicated that long-term studies evaluating cardiovascular risk will be     required  for  approval  of  new NSAID products that may be used on an     <font color="blue">intermittent</font>  or <font color="blue">chronic basis</font></td>
    </tr>
    <tr>
      <td>For example, we believe that long-term     <font color="blue">cardiovascular <font color="blue">safety studies</font> will</font> be required for NDA approval of our oral     lornoxicam  <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We do not know to what extent the FDA’s     <font color="blue">actions may otherwise <font color="blue">adversely affect</font></font> or delay the <font color="blue">approvability</font> of our     <font color="blue">product <font color="blue">candidates</font></font> which contain NSAIDs</td>
    </tr>
    <tr>
      <td>If we, or our current or <font color="blue">future <font color="blue"><font color="blue">collaborator</font>s</font></font>, do not obtain and maintain     required <font color="blue"><font color="blue">regulatory</font> approval</font>s for one or more of our <font color="blue">product <font color="blue">candidates</font></font>, we     will be unable to <font color="blue">commercialize</font> those <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Further, if we are     delayed  in obtaining or unable to obtain, any required approvals, our     <font color="blue"><font color="blue"><font color="blue">collaborator</font>s</font> may</font> be entitled to terminate their <font color="blue"><font color="blue">agreement</font>s</font> with us or     reduce or eliminate their payments to us under these <font color="blue"><font color="blue">agreement</font>s</font> or we may be     required to <font color="blue">pay <font color="blue">termination</font> payments under</font> these <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> under <font color="blue">development</font> are subject to extensive domestic     and  foreign  regulation</td>
    </tr>
    <tr>
      <td>The  FDA regulates, among other things, the     <font color="blue">development</font>,  testing,  <font color="blue">manufacture</font>, safety, efficacy, record keeping,     labeling, storage, approval, advertisement, promotion, sale and <font color="blue">distribution</font>     of <font color="blue">pharmaceutical products</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In order to market our     products  abroad,  we <font color="blue">must comply with</font> extensive <font color="blue">regulation by foreign</font>     <font color="blue"><font color="blue">government</font>s</font></td>
    </tr>
    <tr>
      <td>If  we are unable to obtain and maintain FDA and foreign     <font color="blue">government</font> approvals for our <font color="blue">product <font color="blue">candidates</font></font>, we, alone or through our     <font color="blue"><font color="blue">collaborator</font>s</font>,  will  not be permitted to sell them</td>
    </tr>
    <tr>
      <td>Failure to obtain     <font color="blue">regulatory</font>  approval  for  a  product  candidate  will prevent us from     <font color="blue">commercializing</font> that <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>None of our <font color="blue">product <font color="blue">candidates</font></font> have     been approved for sale <font color="blue">in the US </font>or any <font color="blue">foreign market</font> and they may never     be approved</td>
    </tr>
    <tr>
      <td>In the US, a separate NDA or supplement must be filed <font color="blue">with respect</font> to each     <font color="blue">indication</font> for which <font color="blue">marketing approval</font> of a product is sought</td>
    </tr>
    <tr>
      <td>Each NDA, in     turn,  requires  the successful <font color="blue">completion</font> of preclinical, toxicology,     <font color="blue">genotoxicity</font>  and  <font color="blue">carcinogenicity</font> studies, as well as <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue">demonstrating</font> the safety and efficacy of the product for that particular     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>We may not receive <font color="blue"><font color="blue">regulatory</font> approval</font> of any of the NDAs that     we file with the FDA or of any approval <font color="blue">application</font>s we <font color="blue">may seek outside</font> the     US       Further, our current or future <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> may terminate, or     require  us  to  make  certain  payments  to our <font color="blue"><font color="blue">collaborator</font>s</font>, or our     <font color="blue"><font color="blue"><font color="blue">collaborator</font>s</font> may</font> have the right to terminate their <font color="blue"><font color="blue">agreement</font>s</font> with us or     reduce or eliminate their payments to us under these <font color="blue"><font color="blue">agreement</font>s</font>, <font color="blue">based on</font>     our <font color="blue">inability</font> to obtain, or delays in obtaining, <font color="blue"><font color="blue">regulatory</font> approval</font> for our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>For example, under our <font color="blue">current <font color="blue">collaboration</font> <font color="blue">agreement</font></font>     with Valeant NA, we may elect to withdraw the NDA, if we determine that     <font color="blue">additional</font> studies or data that are required by the FDA for approval of the     NDA  <font color="blue">would jeopardize</font> the <font color="blue">commercial viability</font> of MT 300 or exceed our     <font color="blue">financial resources available</font> for MT 300</td>
    </tr>
    <tr>
      <td>If we notify <font color="blue">Valeant NA </font>of this     situation and <font color="blue">Valeant NA </font>elects not to assume control of efforts to seek     approval of the NDA, then upon notice from Valeant, the <font color="blue">agreement</font> would     terminate and we would be required to pay to <font color="blue">Valeant NA </font>a <font color="blue">withdrawal fee</font> of     dlra1dtta0  million</td>
    </tr>
    <tr>
      <td>We have <font color="blue">begun discussions</font> regarding <font color="blue">termination</font> of our     <font color="blue">commercialization</font> <font color="blue">agreement</font> with <font color="blue">Valeant NA </font>On July 21, 2005, we received a     <font color="blue">letter from</font> <font color="blue">Valeant NA </font><font color="blue">seeking payment</font> of the dlra1 million <font color="blue">withdrawal fee</font>     required <font color="blue">under certain <font color="blue">conditions</font> under</font> the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We do not believe     that the <font color="blue">withdrawal fee</font> is <font color="blue">payable <font color="blue">based on</font></font> our receipt of a not-approvable     <font color="blue">letter from</font> the <font color="blue">FDA                                           </font>16     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font><font color="blue">with respect</font> to our <font color="blue">NDA for MT </font>300</td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font> requires that unresolved     disputes  by the parties be referred to the <font color="blue">respective chief executive</font>     officers for resolution</td>
    </tr>
    <tr>
      <td>If <font color="blue">still unresolved</font>, the <font color="blue">agreement</font> provides for     binding  <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td><font color="blue">Valeant NA </font>has disputed our <font color="blue">conclusion</font> that the     <font color="blue">withdrawal fee</font> is not payable and has indicated its intention to pursue the     <font color="blue">dispute resolution provisions provided</font> for in the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We can give no     assurance that <font color="blue">Valeant NA </font>will agree to <font color="blue">termination</font> terms acceptable to us     or  that  we  will  not be required to pay <font color="blue">Valeant NA </font>the dlra1dtta0 million     <font color="blue">withdrawal fee</font></td>
    </tr>
    <tr>
      <td>If we or our contract <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> do not maintain required <font color="blue">regulatory</font>     approvals, we may not be able to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Approval of a     product  candidate  may  be  <font color="blue">conditioned</font>  upon certain limitations and     <font color="blue">restrictions as</font> to the drug’s use, or upon the conduct of <font color="blue">further studies</font>,     and is subject to <font color="blue">continuous review</font></td>
    </tr>
    <tr>
      <td>The FDA may also require us to conduct     <font color="blue">additional</font> post-approval studies</td>
    </tr>
    <tr>
      <td>These post-approval studies may include     <font color="blue">carcinogenicity</font> studies in animals or <font color="blue">further human <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td>The     later  <font color="blue">discovery</font>  of  <font color="blue">previously</font>  unknown  problems  with the product,     <font color="blue"><font color="blue">manufacture</font>r</font> or <font color="blue"><font color="blue">manufacturing</font> facility may</font> result in <font color="blue">criminal prosecution</font>,     civil  penalties,  recall  or seizure of products, or total or partial     suspension of production, as well as other <font color="blue">regulatory</font> action against our     <font color="blue">product <font color="blue">candidates</font></font> or us</td>
    </tr>
    <tr>
      <td>If approvals are withdrawn for a product, or if a     product is seized or recalled, we would be unable to sell that product and     <font color="blue">therefore would</font> not receive any <font color="blue">revenues from</font> that product</td>
    </tr>
    <tr>
      <td>We and our contract <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> are required to comply with the applicable     FDA current <font color="blue">Good Manufacturing Practices </font>(“cGMP”) <font color="blue">regulations</font>, which include     <font color="blue"><font color="blue">requirement</font>s</font> relating to <font color="blue">quality control</font> and quality assurance, as well as     the <font color="blue">corresponding maintenance</font> of records and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue"><font color="blue">manufacturing</font> facilities must</font> be <font color="blue">approved by</font> the FDA before they     can  be used to <font color="blue">manufacture</font> our <font color="blue">product <font color="blue">candidates</font></font>, and are subject to     <font color="blue">additional</font> FDA inspection</td>
    </tr>
    <tr>
      <td>We, or our third-party <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font>, may not be     able to comply with cGMP <font color="blue">regulations</font> <font color="blue">or other FDA </font><font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>,     <font color="blue">which could</font> result in a delay or an <font color="blue">inability</font> to <font color="blue">manufacture</font> the products</td>
    </tr>
    <tr>
      <td><font color="blue">Labeling </font>and promotional <font color="blue">activities</font> are subject to scrutiny by the FDA and     state <font color="blue">regulatory</font> agencies and, in some <font color="blue">circumstances</font>, the Federal Trade     Commission</td>
    </tr>
    <tr>
      <td>FDA <font color="blue"><font color="blue">enforcement</font> policy prohibits</font> the marketing of unapproved     <font color="blue">products as well as</font> the marketing of <font color="blue">approved products</font> for unapproved, or     off-label, uses</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> and the FDA’s <font color="blue">interpretation</font> of them may     impair  our  ability  to <font color="blue"><font color="blue">effective</font>ly market products</font> for which we gain     approval</td>
    </tr>
    <tr>
      <td>Failure to comply with these <font color="blue"><font color="blue">requirement</font>s</font> can result in federal     and state <font color="blue">regulatory</font> <font color="blue">enforcement</font> action</td>
    </tr>
    <tr>
      <td>Further, we may not obtain the     labeling claims we believe are <font color="blue">necessary</font> or desirable for the promotion of     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Because we do not believe it is possible to convince the FDA to reverse its     <font color="blue">conclusion</font> as stated in its not-<font color="blue">approvable letter</font> for MT 300, we do not     expect to receive any <font color="blue">revenue from sales</font> of MT 300 in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In October 2003, we received a not-<font color="blue"><font color="blue">approvable letter</font> from</font> the FDA related to     our <font color="blue">NDA for MT </font>300</td>
    </tr>
    <tr>
      <td>The letter was <font color="blue">issued <font color="blue">based on</font></font> the FDA’s <font color="blue">conclusion</font> that     we had not submitted substantial evidence of <font color="blue"><font color="blue">effective</font>ness</font> for MT 300 as an     <font color="blue">acute treatment</font> for migraine</td>
    </tr>
    <tr>
      <td>The FDA noted that, although MT 300 provided a     statistically  <font color="blue"><font color="blue">significant</font> improvement over placebo on</font> the pre-defined     endpoint of sustained pain relief at 24 hours post dose as well as relief of     pain  at  two  hours  post  dose, MT 300 failed to achieve statistical     <font color="blue">significance versus placebo</font> for the relief of all of the <font color="blue">ancillary symptoms</font>     of migraine (nausea, photophobia and phonophobia) at two hours</td>
    </tr>
    <tr>
      <td>Further, the     FDA noted that the incidence of nausea, one of the <font color="blue">associated symptoms</font> of     migraine, was <font color="blue">statistically <font color="blue"><font color="blue">significant</font>ly</font> higher following</font> MT 300 treatment     <font color="blue">versus placebo at two hours</font></td>
    </tr>
    <tr>
      <td>Since our receipt of the not-<font color="blue">approvable letter</font>,     we have had <font color="blue">continuing communications with</font> the FDA regarding the MT 300 NDA     Based upon our <font color="blue">understandings from</font> our most <font color="blue">recent communications with</font> the     FDA and our understanding of the FDA’s <font color="blue">current standards</font> for approval of     migraine  drugs,  we  do not believe it is possible to reverse the not     <font color="blue">approvable status</font> of the MT 300 NDA Therefore, we do not believe that we     will receive any <font color="blue">revenue from sales</font> of MT 300 <font color="blue">in the US </font>      Our  reliance  on  <font color="blue"><font color="blue">collaboration</font>s</font>  with  third  parties to develop and     <font color="blue">commercialize</font> our products is subject to <font color="blue">inherent risks</font> and may result in     delays in product <font color="blue">development</font> and lost or reduced revenues, restricting our     ability  to  <font color="blue">commercialize</font>  our  products  and <font color="blue"><font color="blue">adversely affect</font>ing</font> our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Under our <font color="blue">current strategy</font>, and for the <font color="blue">foreseeable future</font>, we expect to     depend  upon  <font color="blue"><font color="blue">collaboration</font>s</font> with <font color="blue">third parties</font> to develop our product     <font color="blue">candidates</font> and we expect to <font color="blue">depend <font color="blue">substantially</font> upon <font color="blue">third parties</font></font> to     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>As a result, our ability to develop, obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> of, <font color="blue">manufacture</font> and <font color="blue">commercialize</font> our existing and any     future <font color="blue">product <font color="blue">candidates</font></font> depends upon our ability to maintain existing, and     <font color="blue">enter into</font> and maintain new, contractual and <font color="blue"><font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with</font>     others</td>
    </tr>
    <tr>
      <td>We also engage, and intend in the future to continue to engage,     contract <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and <font color="blue"><font color="blue"><font color="blue">clinical trial</font> investigator</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">identification</font> of <font color="blue">new compounds</font> or <font color="blue">product <font color="blue">candidates</font></font> for     <font color="blue">development</font>  has led us, and <font color="blue">may continue</font> to require us, to <font color="blue">enter into</font>     license  or  other  <font color="blue">collaborative</font>  <font color="blue"><font color="blue">agreement</font>s</font>  with  others, including     <font color="blue">pharmaceutical companies</font> and research <font color="blue">institutions</font>, such as our license and     <font color="blue">development</font>  <font color="blue">agreement</font>  with  Nycomed pursuant to which we obtained an     exclusive  license  to  certain  rights  to  develop,  <font color="blue">manufacture</font> and     <font color="blue">commercialize</font> products containing lornoxicam</td>
    </tr>
    <tr>
      <td>Such <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font>     for the <font color="blue">acquisition</font> of <font color="blue">new compounds</font> or <font color="blue">product <font color="blue">candidates</font></font> would typically     require  us  to  pay  <font color="blue">license fees</font>, make <font color="blue">milestone payments</font> and/or pay     royalties</td>
    </tr>
    <tr>
      <td>Furthermore, these <font color="blue"><font color="blue">agreement</font>s</font> may result in our revenues being     lower than if we developed our <font color="blue">product <font color="blue">candidates</font></font> ourselves and in our loss     of <font color="blue">control over</font> the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>Contractors  or  <font color="blue"><font color="blue">collaborator</font>s</font>  may  have the right to terminate their     <font color="blue"><font color="blue">agreement</font>s</font> with us or reduce their payments to us under those <font color="blue"><font color="blue">agreement</font>s</font> on     limited or no notice and for <font color="blue">reasons outside</font> of our control</td>
    </tr>
    <tr>
      <td>We currently     have a <font color="blue">collaboration</font> with GSK for the <font color="blue">development</font> and <font color="blue">commercialization</font> of     certain triptan <font color="blue">combination</font>s using our MT 400 <font color="blue">technology</font> <font color="blue">in the US </font>and a     <font color="blue">collaboration</font>  with  Valeant  NA  in  the US for the <font color="blue">development</font> and     <font color="blue">commercialization</font> of MT 300</td>
    </tr>
    <tr>
      <td>In these <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font>, as well as     under our lornoxicam license <font color="blue">agreement</font> with Nycomed described above, our     <font color="blue"><font color="blue">collaborator</font>s</font> have the right to terminate the <font color="blue">agreement</font> upon a <font color="blue">default by</font>     us</td>
    </tr>
    <tr>
      <td>Additionally, GSK may reduce the <font color="blue">royalties on net</font>     sales of <font color="blue">products payable</font> to us under the <font color="blue">agreement</font> if <font color="blue">generic <font color="blue">competitors</font></font>     attain a pre-determined share of the market for <font color="blue">products marketed under</font> the     <font color="blue">agreement</font>, or if GSK owes a royalty to one or more <font color="blue">third parties</font> for rights     it <font color="blue">licenses from</font> those <font color="blue">third parties</font> to <font color="blue">commercialize</font> products marketed     under the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Valeant NA </font>is entitled to terminate its <font color="blue">agreement</font> with     us and a dlra1dtta0 million <font color="blue">withdrawal fee</font> payable by us if we choose to withdraw     the <font color="blue">NDA for MT </font>300 for commercial or <font color="blue">financial reasons under</font> the <font color="blue">conditions</font>     specified in the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Due to our belief that the FDA will not approve     the <font color="blue">NDA for MT </font>300, we have <font color="blue">begun discussions</font> with <font color="blue">Valeant NA </font>regarding     <font color="blue">termination</font> of our <font color="blue">agreement</font> and <font color="blue">Valeant NA </font>has <font color="blue">demanded payment</font> of the dlra1dtta0     million <font color="blue">withdrawal fee</font></td>
    </tr>
    <tr>
      <td>If our current or future licensees exercise <font color="blue">termination</font> rights they may     have,  or  if  these license <font color="blue"><font color="blue">agreement</font>s</font> terminate because of delays in     obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s, or for other reasons, and we are not able to     <font color="blue">establish replacement</font> or <font color="blue">additional</font> research and <font color="blue">development</font> <font color="blue"><font color="blue">collaboration</font>s</font>     or <font color="blue">licensing <font color="blue"><font color="blue">arrangement</font>s</font></font>, we may not be able to develop and <font color="blue">commercialize</font>     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Moreover, any future <font color="blue"><font color="blue">collaboration</font>s</font> or license     <font color="blue"><font color="blue">arrangement</font>s</font> we may <font color="blue">enter into</font> may not be on terms favorable to us</td>
    </tr>
    <tr>
      <td>A <font color="blue">further risk</font> we <font color="blue">face with</font> our <font color="blue"><font color="blue">collaboration</font>s</font> is that business <font color="blue">combination</font>s     and changes in the <font color="blue">collaborator</font> or their business <font color="blue">strategy may adversely</font>     affect their <font color="blue">willingness</font> or ability to complete their <font color="blue">obligations</font> to us</td>
    </tr>
    <tr>
      <td>Our current or any future <font color="blue"><font color="blue">collaboration</font>s</font> or license <font color="blue"><font color="blue">arrangement</font>s</font> ultimately     may not be successful</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue"><font color="blue">collaborator</font>s</font> typically allow     them  <font color="blue">discretion</font>  in  electing  whether  to pursue various <font color="blue">regulatory</font>,     <font color="blue">commercialization</font> and other <font color="blue">activities</font> or <font color="blue">with respect</font> to the timing of the     <font color="blue">development</font>, such as our <font color="blue">agreement</font> with GSK under which GSK determines,     among other things, the exact <font color="blue">formulation</font> and <font color="blue">composition</font> of the product     <font color="blue">candidates</font> using our MT 400 <font color="blue">technology</font> for use in the Trexima clinical     trials</td>
    </tr>
    <tr>
      <td>If  any  <font color="blue">collaborator</font> were to breach its <font color="blue">agreement</font> with us or     otherwise fail to conduct <font color="blue">collaborative</font> <font color="blue">activities</font> in a timely or successful     manner, the pre-clinical or clinical <font color="blue">development</font> or <font color="blue">commercialization</font> of the     affected  product  candidate  or  <font color="blue">research program would</font> be delayed or     terminated</td>
    </tr>
    <tr>
      <td>Any  delay  or  <font color="blue">termination</font>  of  clinical  <font color="blue">development</font> or     <font color="blue">commercialization</font> would delay or eliminate our <font color="blue">potential product revenues</font></td>
    </tr>
    <tr>
      <td>Further, our <font color="blue"><font color="blue"><font color="blue">collaborator</font>s</font> may</font> be able to exercise control, under certain     <font color="blue">circumstances</font>, over our ability to protect our <font color="blue"><font color="blue">patent rights</font> under patents</font>     <font color="blue">covered by</font> the applicable <font color="blue">collaboration</font> <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>For example, under our     <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font> with</font> GSK, GSK has the first right to enforce our MT     400  patents  and  would  have exclusive <font color="blue">control over</font> such <font color="blue">enforcement</font>     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Other risks <font color="blue">associated with</font> our <font color="blue">collaborative</font> and contractual <font color="blue"><font color="blue">arrangement</font>s</font>     <font color="blue">with others</font> include the following:           •   we may not have day-to-day <font color="blue">control over</font> the <font color="blue">activities</font> of our     <font color="blue">contractors</font> or <font color="blue"><font color="blue">collaborator</font>s</font>;           •   <font color="blue">third parties</font> may not fulfill their <font color="blue">regulatory</font> or other <font color="blue">obligations</font>;           •   we may not realize the contemplated or expected <font color="blue">benefits from</font>     <font color="blue">collaborative</font> or other <font color="blue"><font color="blue">arrangement</font>s</font>; and           •   dis<font color="blue"><font color="blue">agreement</font>s</font> may arise regarding a breach of the <font color="blue">arrangement</font>, the     <font color="blue">interpretation</font> of the <font color="blue">agreement</font>, ownership of <font color="blue">proprietary</font> rights, clinical     results or <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>These  factors  could lead to delays in the <font color="blue">development</font> of our product     <font color="blue">candidates</font> and/or the <font color="blue">commercialization</font> of our products or reduction in the     <font color="blue">milestone payments</font> we receive from our <font color="blue"><font color="blue">collaborator</font>s</font>, or could result in our     not being able to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Further, dis<font color="blue"><font color="blue">agreement</font>s</font> with     our <font color="blue">contractors</font> or <font color="blue"><font color="blue">collaborator</font>s</font> could require or result in <font color="blue">litigation</font> or     <font color="blue">arbitration</font>, which would be time-consuming and expensive</td>
    </tr>
    <tr>
      <td>Our ultimate     success may depend upon the success and <font color="blue">performance on</font> the part of these     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain these <font color="blue">relationships</font> or <font color="blue">establish new</font>     <font color="blue">relationships</font> as required, <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> and/or the     <font color="blue">commercialization</font> of our <font color="blue">products will</font> be delayed or may never be realized</td>
    </tr>
    <tr>
      <td>A <font color="blue">collaborator</font> may withdraw support or cease to perform work on our product     <font color="blue">candidates</font> if the <font color="blue">collaborator</font> determines to develop its own competing     <font color="blue">product candidate</font> instead</td>
    </tr>
    <tr>
      <td>We have entered into <font color="blue">collaboration</font> and license <font color="blue"><font color="blue">agreement</font>s</font>, and expect to     continue to <font color="blue">enter into</font> such <font color="blue"><font color="blue">agreement</font>s</font>, with companies that have products     and are developing new <font color="blue">product <font color="blue">candidates</font></font> that compete or <font color="blue">may compete with</font>     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If one of our <font color="blue"><font color="blue">collaborator</font>s</font> should decide that the     product or a <font color="blue">product candidate</font> that the <font color="blue">collaborator</font> is developing would be     more profitable for the <font color="blue">collaborator</font> than our <font color="blue">product candidate</font> <font color="blue">covered by</font>     the  <font color="blue">collaboration</font> or license <font color="blue">agreement</font>, the <font color="blue">collaborator</font> may withdraw     support  for  our  <font color="blue">product candidate</font> or may cease to perform under our     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In the event of a <font color="blue">termination</font> of the <font color="blue">collaborator</font>’s <font color="blue">agreement</font>     <font color="blue">upon such cessation</font> of performance, we would need to negotiate an <font color="blue">agreement</font>                                           18     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>with  another  <font color="blue">collaborator</font>  in  order to continue the <font color="blue">development</font> and     <font color="blue">commercialization</font> efforts for the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>If we were <font color="blue">unsuccessful</font>     in  <font color="blue">negotiating</font>  another <font color="blue">agreement</font>, we might have to cease <font color="blue">development</font>     <font color="blue">activities</font>  of  the  particular <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> and     <font color="blue">commercialization</font>  <font color="blue">agreement</font> with GSK is subject to this risk</td>
    </tr>
    <tr>
      <td>GSK has     publicly  disclosed  that  it  is exploring the <font color="blue">development</font> of several     early-stage compounds for the treatment of migraine</td>
    </tr>
    <tr>
      <td>If GSK decides to focus     its <font color="blue">development</font> and <font color="blue">commercialization</font> efforts on its own <font color="blue">products rather</font>     <font color="blue">than continuing</font> to work <font color="blue">with us on</font> Trexima or any other <font color="blue">product <font color="blue">candidates</font></font>     that may be developed under the <font color="blue">agreement</font>, it has the ability to terminate     our <font color="blue">agreement</font> upon 90 days’ written notice</td>
    </tr>
    <tr>
      <td>In such a case, we would need to     <font color="blue">enter into</font> a new <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">agreement</font> and would need     to  start  the  <font color="blue">development</font> process all over again</td>
    </tr>
    <tr>
      <td>If we were able to     negotiate a new <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">agreement</font> to develop our     MT 400 <font color="blue">technology</font>, which is not certain, we <font color="blue">would face delays</font> and redundant     expenses in that <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We need to maintain current <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue"><font color="blue">agreement</font>s</font>     with  third  parties  that  possess  sales, marketing and <font color="blue">distribution</font>     <font color="blue">capabilities</font>,  or <font color="blue">establish internally</font> the <font color="blue">capability</font> to perform these     functions,  in  order  to <font color="blue"><font color="blue">successfully</font> market</font> and sell our <font color="blue">future drug</font>     products</td>
    </tr>
    <tr>
      <td>We have no sales or <font color="blue">distribution</font> personnel or <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If we are unable     to maintain current <font color="blue"><font color="blue">collaboration</font>s</font> or <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue"><font color="blue">collaboration</font>s</font>     <font color="blue">with established pharmaceutical</font> or <font color="blue">pharmaceutical services companies</font> to     provide those <font color="blue">capabilities</font>, or, <font color="blue"><font color="blue">alternative</font>ly</font>, we are unable to develop     <font color="blue">internally sales</font> and <font color="blue">distribution</font> <font color="blue">capabilities</font>, we will not be able to     <font color="blue">successfully</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>To the extent that we <font color="blue">enter into</font>     marketing and sales <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">third parties</font>, our revenues, if any,     will be <font color="blue">affected by</font> the sales and marketing efforts of those <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Further, we <font color="blue">cannot guarantee</font> that, should we elect to develop our own sales     and <font color="blue">distribution</font> <font color="blue">capabilities</font>, we would have <font color="blue">sufficient resources</font> to do so,     or would be able to hire the <font color="blue">qualified sales</font> and <font color="blue">marketing personnel</font> we     would need</td>
    </tr>
    <tr>
      <td>We need to conduct preclinical, toxicology, <font color="blue">genotoxicity</font> and <font color="blue">carcinogenicity</font>     and other <font color="blue">safety studies</font>, and <font color="blue"><font color="blue">clinical trial</font>s</font> for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">unanticipated</font> results, <font color="blue">unforeseen costs</font> or delays in the conduct of     these studies or trials, or the need to conduct <font color="blue">additional</font> studies or trials     or to seek to persuade the FDA to evaluate the results of a study or trial     in a <font color="blue">different</font> manner, could reduce, delay or eliminate our receipt of     revenues for one or more of our <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">adversely affect</font> our     ability to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Generally,  we <font color="blue">must demonstrate</font> the efficacy and safety of our product     <font color="blue">candidates</font> before approval to market can be obtained from the FDA or the     <font color="blue">regulatory</font> authorities in other countries</td>
    </tr>
    <tr>
      <td>Our existing and <font color="blue">future product</font>     <font color="blue">candidates</font>  are and will be in <font color="blue">various stages</font> of clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending  </font>upon  the  type  of  <font color="blue">product candidate</font> and the stage of the     <font color="blue">development</font>  process  of a <font color="blue">product candidate</font>, we will need to complete     preclinical, toxicology, <font color="blue">genotoxicity</font> and <font color="blue">carcinogenicity</font> and other safety     studies, as well as <font color="blue"><font color="blue">clinical trial</font>s</font>, on these <font color="blue">product <font color="blue">candidates</font></font> before we     submit marketing <font color="blue">application</font>s in the <font color="blue">United States</font> and abroad</td>
    </tr>
    <tr>
      <td>These studies     and trials can be very costly and time-consuming</td>
    </tr>
    <tr>
      <td>For example, long-term     cardiovascular <font color="blue">safety studies</font>, such as those the FDA has <font color="blue">indicated will</font> be     required for approval of certain <font color="blue">product <font color="blue">candidates</font></font> containing NSAIDs,     typically take <font color="blue">approximately three years</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">rely on third</font>     parties to perform <font color="blue"><font color="blue">significant</font> aspects</font> of our studies and <font color="blue"><font color="blue">clinical trial</font>s</font>,     introducing <font color="blue">additional</font> sources of risk into our <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>It  should  be  noted  that the results of our <font color="blue"><font color="blue">clinical trial</font>s</font> are not     <font color="blue">necessarily predictive</font> of results we will obtain in <font color="blue">subsequent clinical</font>     trials</td>
    </tr>
    <tr>
      <td>This may occur for many reasons, including, <font color="blue">among others</font>, the     <font color="blue">variability</font> of <font color="blue">patient characteristics</font>, including <font color="blue">patient symptoms at</font> the     time of <font color="blue">study treatment</font>, the <font color="blue">larger scale testing</font> of patients in later     trials, or <font color="blue">differences</font> in <font color="blue">formulation</font> or doses of the <font color="blue">product candidate</font> used     in <font color="blue">later trials</font></td>
    </tr>
    <tr>
      <td>For example, our results from the first of our two Phase 3     <font color="blue">pivotal <font color="blue">clinical trial</font></font> of Trexima <font color="blue">differed from</font> the results of our second     Phase 3 <font color="blue">clinical trial</font> and <font color="blue">the Phase </font>2 proof-of-concept trial of MT 400 that     we <font color="blue">conducted prior</font> to <font color="blue">entering into</font> our <font color="blue">collaboration</font> with GSK Whereas in     <font color="blue">the Phase </font>2 trial statistical significance was <font color="blue">reached at two hours over</font>     placebo  in the relief of all <font color="blue">associated symptoms</font> of migraine (nausea,     photophobia and phonophobia), in the first Phase 3 study Trexima failed to     achieve <font color="blue">statistical significance at two hours compared</font> to placebo in the     relief of nausea</td>
    </tr>
    <tr>
      <td>In the second Phase 3 <font color="blue">pivotal <font color="blue">clinical trial</font></font>, <font color="blue">Trexima     </font><font color="blue">demonstrated</font>  <font color="blue">superiority</font>  over  the individual <font color="blue">components</font> measured by     sustained pain-free response (p<0dtta001 vs</td>
    </tr>
    <tr>
      <td>sumatriptan)     and met all other <font color="blue">regulatory</font> endpoints versus placebo</td>
    </tr>
    <tr>
      <td>The successful <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> depends upon many factors,     including the rate of <font color="blue">enrollment</font> of patients</td>
    </tr>
    <tr>
      <td>If we are unable to recruit     <font color="blue">sufficient clinical patients during</font> the <font color="blue">appropriate period</font>, we may need to     delay our <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">incur <font color="blue">significant</font></font> <font color="blue">additional</font> costs</td>
    </tr>
    <tr>
      <td>We also     rely  on  the  compliance of our <font color="blue"><font color="blue"><font color="blue">clinical trial</font> investigator</font>s</font> with FDA     <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> and <font color="blue">noncompliance</font> can result in <font color="blue">disqualification</font> of     a <font color="blue"><font color="blue">clinical trial</font> investigator</font> and data that is unusable</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">FDA or Institutional Review Boards </font>may require us to conduct <font color="blue">additional</font>     trials or delay, restrict or <font color="blue">discontinue</font> our <font color="blue"><font color="blue">clinical trial</font>s</font> on various     grounds, including a finding that the subjects or patients are being exposed     to an unacceptable <font color="blue">health risk</font></td>
    </tr>
    <tr>
      <td>For example, <font color="blue">even though</font> we are entitled to     submit an NDA for Trexima as a 505(b)(2) <font color="blue">application</font>, the FDA may require us     to conduct more studies or <font color="blue">trials than</font> we now believe are <font color="blue">necessary</font> or     required</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">even though</font> we may have completed all <font color="blue"><font color="blue">clinical trial</font>s</font> for a product     candidate  that  were planned for submission in support of a marketing     <font color="blue">application</font>, we may be required to conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>,     studies  or  <font color="blue">investigations</font>  to support our marketing <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>In     addition, we and/or our marketing or <font color="blue">development</font> partners may                                           19     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>determine that pre-approval marketing support studies should be conducted</td>
    </tr>
    <tr>
      <td><font color="blue">Unanticipated </font><font color="blue"><font color="blue">adverse outcome</font>s</font> of <font color="blue">such studies</font>, including <font color="blue">recognition</font> of     certain  risks  to human subjects, could a have material <font color="blue">impact on</font> the     approval of filed or planned market <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We may also determine from     time to time that it would be <font color="blue">necessary</font> to seek to <font color="blue">provide justification</font> to     the FDA or other <font color="blue">regulatory</font> agency that would result in <font color="blue">evaluation</font> of the     results of a study or <font color="blue">clinical trial</font> in a manner that <font color="blue">differs from</font> the way     the <font color="blue">regulatory</font> agency initially or <font color="blue">customarily evaluated</font> the results</td>
    </tr>
    <tr>
      <td>In     addition, we may have unexpected results that require us to reconsider the     need for <font color="blue">certain studies</font> or trials</td>
    </tr>
    <tr>
      <td>For example, results from a <font color="blue">genotoxicity</font>     <font color="blue">study involving</font> MT 400 may require us to <font color="blue">conduct chronic toxicology</font> and     <font color="blue">carcinogenicity</font> studies for Trexima or other MT 400 <font color="blue">product <font color="blue">candidates</font></font> we     may develop</td>
    </tr>
    <tr>
      <td>Once submitted, an NDA requires FDA approval before we can distribute or     <font color="blue">commercialize</font> the <font color="blue">product described</font> in the <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>Even if we determine     that  data  from  our  clinical  trials,  toxicology, <font color="blue">genotoxicity</font> and     <font color="blue">carcinogenicity</font> studies are positive, we <font color="blue">cannot assure</font> you that the FDA,     after completing its analysis, will not determine that the trials or studies     should  have  been conducted or <font color="blue">analyzed <font color="blue">different</font>ly</font>, and thus reach a     <font color="blue">different</font>  <font color="blue">conclusion</font> from that <font color="blue">reached by us</font>, or request that further     trials, studies or analyses be conducted</td>
    </tr>
    <tr>
      <td>For example, although we believe     that we provided the <font color="blue">necessary</font> data to <font color="blue">support approval</font> of the NDAs for MT     100 and MT 300, the FDA issued not-<font color="blue">approvable letter</font>s for the MT 100 and MT     300 NDAs on May 28, 2004 and October 17, 2003, respectively, and <font color="blue">based upon</font>     our <font color="blue">understandings from</font> our <font color="blue">most recent communication with</font> the FDA and our     understanding of the FDA’s <font color="blue">current standards</font> for approval of <font color="blue">migraine drugs</font>,     we do not believe it is possible to reverse the not <font color="blue">approvable status</font> of the     <font color="blue">NDA for MT </font>300</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">based upon</font> our receipt of the not approvable     letter for MT 100 and the outcome of an August 2005 <font color="blue">FDA Advisory Committee     </font>meeting relating to the <font color="blue">potential risk</font> of <font color="blue">tardive dyskinesia</font> <font color="blue">associated with</font>     the  use  of  one of the <font color="blue">components</font> of MT 100, we made the decision to     <font color="blue">discontinue</font> further <font color="blue">development</font> of MT 100 <font color="blue">in the US </font>      The FDA may also require data in certain subpopulations, such as pediatric     use,  or,  if  <font color="blue">such studies</font> were not <font color="blue">previously</font> completed, may require     long-term <font color="blue">carcinogenicity</font> studies, prior to NDA approval, unless we can     obtain a waiver of such a <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>We face similar <font color="blue">regulatory</font> hurdles in     other countries to those that we face <font color="blue">in the US </font>      Our costs <font color="blue">associated with</font> our human <font color="blue"><font color="blue">clinical trial</font>s</font> vary <font color="blue">based on</font> a number     of factors, including:           •   the order and timing of clinical <font color="blue">indication</font>s pursued;           •   the extent of <font color="blue">development</font> and financial support from <font color="blue">collaborative</font>     parties, if any;           •   the need to conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> or studies;           •   the number of patients required for <font color="blue">enrollment</font>;           •   the <font color="blue">difficult</font>y of obtaining <font color="blue">sufficient patient populations</font> and     <font color="blue">clinicians</font>;           •   the <font color="blue">difficult</font>y of obtaining <font color="blue">clinical supplies</font> of our product     <font color="blue">candidates</font>; and           •   <font color="blue">government</font>al and <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>We  <font color="blue">currently depend</font> and will in the future depend on <font color="blue">third parties</font> to     <font color="blue">manufacture</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If these <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> fail to meet our     <font color="blue"><font color="blue">requirement</font>s</font> or any <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, the product <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> will be delayed</td>
    </tr>
    <tr>
      <td>We do not have, and have no plans to develop, the internal <font color="blue">capability</font> to     <font color="blue">manufacture</font> either <font color="blue">clinical trial</font> or <font color="blue">commercial quantities</font> of products that     we  may  develop  or  have under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We rely upon third-party     <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> to <font color="blue">supply us with</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We also need supply     contracts to sell our <font color="blue">products commercially</font></td>
    </tr>
    <tr>
      <td>There is no guarantee that     <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> that <font color="blue">enter into</font> <font color="blue">commercial supply contracts</font> with us will be     <font color="blue">financially viable entities going forward</font>, or will not <font color="blue">otherwise breach</font> or     terminate  their  <font color="blue"><font color="blue">agreement</font>s</font>  with us</td>
    </tr>
    <tr>
      <td>If we do not have the <font color="blue">necessary</font>     <font color="blue">commercial supply contracts</font>, or if our current <font color="blue"><font color="blue">manufacture</font>r</font> is, or any of     our future <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> are, unable to satisfy our <font color="blue"><font color="blue">requirement</font>s</font> or meet any     <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, and we are required to <font color="blue">find <font color="blue">alternative</font> sources</font> of     supply, there may be <font color="blue">additional</font> costs and delays in product <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> or we may be required to comply     with <font color="blue">additional</font> <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop and <font color="blue">commercialize</font> products faster than we do or     if their products are superior to ours, our <font color="blue">commercial <font color="blue">opportunities</font> will</font> be     reduced or eliminated</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> will have to <font color="blue">compete with existing</font> and any newly     developed <font color="blue">migraine therapies</font> or therapies for any newly developed product     <font color="blue">candidates</font> for the treatment of other diseases</td>
    </tr>
    <tr>
      <td>There are <font color="blue">also likely</font> to be     numerous <font color="blue">competitors</font> developing <font color="blue">new products</font> to <font color="blue">treat migraine</font> and the other     diseases and <font color="blue">conditions</font> for which we may seek to develop products in the     future, <font color="blue">which could</font> render our <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue"><font color="blue">technologies</font> obsolete</font>     or  non-competitive</td>
    </tr>
    <tr>
      <td>Our primary <font color="blue">competitors</font> will likely include large     <font color="blue">pharmaceutical companies</font> (including, <font color="blue">based upon</font> their <font color="blue">current migraine</font>     portfolios, GSK, Merck &amp; Co, Astra Zeneca, Johnson &amp; Johnson and Pfizer,     Inc</td>
    </tr>
    <tr>
      <td>), bio<font color="blue">technology</font> companies, universities and public and <font color="blue">private research</font>     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Based  upon  their  <font color="blue">migraine portfolios</font> and the overall     <font color="blue">competitiveness</font> of our industry, we believe that we face, and <font color="blue">will continue</font>     to  face,  intense  <font color="blue">competition</font>  from  other  companies  for  securing     <font color="blue"><font color="blue">collaboration</font>s</font> with <font color="blue">pharmaceutical companies</font>, establishing <font color="blue">relationships</font>     with  academic  and  research  <font color="blue">institutions</font>, and acquiring licenses to     <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>Our  <font color="blue">competitors</font>, either alone or with <font color="blue">collaborative</font> parties, may also     succeed <font color="blue">with <font color="blue">technologies</font></font> or products that are more <font color="blue"><font color="blue">effective</font> than</font> any of     our  current or <font color="blue">future <font color="blue">technologies</font></font> or products</td>
    </tr>
    <tr>
      <td>Many of our actual or     potential <font color="blue">competitors</font>, either alone or together with <font color="blue">collaborative</font> parties,     have  <font color="blue">substantially</font> greater financial resources, and almost all of our     <font color="blue">competitors</font> have larger numbers of scientific and <font color="blue">administrative</font> personnel     than we do</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font>, either alone or together with their <font color="blue">collaborative</font>     parties, also have <font color="blue"><font color="blue">significant</font>ly</font> greater experience than we do in:           •   developing <font color="blue">product <font color="blue">candidates</font></font>;           •   undertaking preclinical testing and human <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approval</font>s of <font color="blue">product <font color="blue">candidates</font></font>;     and           •   <font color="blue">manufacturing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td>Accordingly, our actual or potential <font color="blue">competitors</font> may succeed in obtaining     patent  protection,  receiving  FDA  or  other  <font color="blue"><font color="blue">regulatory</font> approval</font> or     <font color="blue">commercializing</font> products before we do</td>
    </tr>
    <tr>
      <td>Any delays we encounter in obtaining     <font color="blue"><font color="blue">regulatory</font> approval</font>s for our <font color="blue">product <font color="blue">candidates</font></font>, such as we are currently     experiencing as a result of the not-<font color="blue">approvable letter</font>s we have received from     the FDA on MT 100 and MT 300, increase this risk</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may also     develop products or <font color="blue">technologies</font> that are superior to those that we are     developing, and render our <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue"><font color="blue">technologies</font> obsolete</font> or     non-competitive</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot <font color="blue">successfully</font> compete with new</font> or existing     products, our marketing and <font color="blue">sales will suffer</font> and we may not ever receive     any <font color="blue">revenues from</font> sales of products or may not receive <font color="blue">sufficient revenues</font>     to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If there is an <font color="blue">adverse outcome</font> in the securities class action or <font color="blue">shareholder</font>     <font color="blue">derivative lawsuits</font> that have been <font color="blue">filed against</font> us or our current or former     <font color="blue">directors</font> and officers, our business may be <font color="blue">materially harmed</font></td>
    </tr>
    <tr>
      <td>Further,     defending  against these <font color="blue">lawsuits may</font> be expensive and <font color="blue">will divert</font> the     attention of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Four purported class <font color="blue">action lawsuits</font> claiming violations of <font color="blue">securities laws</font>     were <font color="blue">filed between</font> June 4 and July 28, 2004 <font color="blue">in the US </font>District Court for     <font color="blue">the Middle District of North Carolina </font>by holders of our <font color="blue">securities against</font>     us and certain of our current and <font color="blue">former officers</font></td>
    </tr>
    <tr>
      <td>These actions have been     <font color="blue">consolidated</font> for pre-trial purposes</td>
    </tr>
    <tr>
      <td>A <font color="blue">fifth case filed on</font> August 6, 2004     has also been <font color="blue">consolidated</font> with those actions for pre-trial purposes</td>
    </tr>
    <tr>
      <td>By     order dated November 4, 2004, the <font color="blue">court appointed</font> a <font color="blue">lead plaintiff</font>, who     filed a <font color="blue">consolidated</font> <font color="blue">amended complaint</font> (<font color="blue">amended complaint</font>) on <font color="blue">December </font>20,     2004</td>
    </tr>
    <tr>
      <td>The <font color="blue">defendants named</font> in the <font color="blue">amended complaint</font> are POZEN and John R     Plachetka, our chairman and <font color="blue">chief executive officer</font></td>
    </tr>
    <tr>
      <td>The complaint alleges     violations of federal <font color="blue">securities laws</font>, including violations of Section 10(b)     of the <font color="blue">Securities <font color="blue">Exchange Act </font></font>of 1934, as amended, and Rule 10b-5, and     violations of Section 20(a) of the <font color="blue">Exchange Act </font>against Dr</td>
    </tr>
    <tr>
      <td>The     <font color="blue">amended complaint</font> alleges that we made false and <font color="blue">misleading statements</font>     <font color="blue">concerning</font> our <font color="blue">product <font color="blue">candidates</font></font> MT 100 and MT 300 during the class period</td>
    </tr>
    <tr>
      <td>The <font color="blue">amended complaint</font> requests certification of a plaintiff class consisting     of purchasers of our <font color="blue">stock between</font> October 4, 2002 and May 28, 2004</td>
    </tr>
    <tr>
      <td>In     January 2005, we moved to dismiss the <font color="blue">amended complaint</font></td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2004, two <font color="blue">derivative actions</font> were <font color="blue"><font color="blue">filed against</font> certain</font> of our     current and former <font color="blue">directors</font> and officers in the <font color="blue">Superior Court </font>for the     County  of Orange in the State of North Carolina</td>
    </tr>
    <tr>
      <td>These actions allege     violations of state law, including breaches of <font color="blue">fiduciary duties</font> and insider     sales, relating to the same allegedly <font color="blue">misleading statements</font> <font color="blue">concerning</font> the     same <font color="blue">product <font color="blue">candidates</font></font> MT 100 and MT 300 that are referenced in the various     purported class <font color="blue">action lawsuits</font></td>
    </tr>
    <tr>
      <td>The cases were <font color="blue">consolidated</font> and assigned to     the <font color="blue">North Carolina Business Court</font></td>
    </tr>
    <tr>
      <td>The plaintiffs in the <font color="blue">derivative actions</font>     filed a <font color="blue">consolidated</font> <font color="blue">amended complaint</font> asserting the same claims as were     asserted in the <font color="blue">original complaints</font></td>
    </tr>
    <tr>
      <td>In May 2005, we filed a motion to     dismiss  the  <font color="blue">consolidated</font> and <font color="blue">amended complaint</font></td>
    </tr>
    <tr>
      <td>In August 2005, oral     arguments were made before the <font color="blue">North Carolina Business Court</font> and, in a     <font color="blue">decision entered on</font> November 10, 2005, the Court dismissed the <font color="blue">consolidated</font>     and <font color="blue">amended complaint</font> “with prejudice”</td>
    </tr>
    <tr>
      <td>As with any <font color="blue">litigation</font> proceeding, we <font color="blue"><font color="blue">cannot predict</font> with certainty</font> the     eventual  outcome of the pending class <font color="blue">action lawsuit described</font> above</td>
    </tr>
    <tr>
      <td>Furthermore, we will have to <font color="blue">incur expenses</font> in <font color="blue">connection with</font> this lawsuit,     which may be substantial</td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">adverse outcome</font>, our business     could  be <font color="blue">materially harmed</font></td>
    </tr>
    <tr>
      <td>Moreover, responding to and defending the     pending <font color="blue">litigation</font> will result in a <font color="blue"><font color="blue">significant</font> diversion</font> of <font color="blue">management</font>’s     attention and resources and an increase in <font color="blue">professional fees</font></td>
    </tr>
    <tr>
      <td>If we are unable to protect our patents or <font color="blue">proprietary</font> rights, or if we are     unable  to  operate  our  business  <font color="blue">without infringing</font> the patents and     <font color="blue">proprietary</font>  rights of others, we may be unable to develop our product     <font color="blue">candidates</font> or <font color="blue">compete <font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical industry places</font> considerable <font color="blue">importance on</font> obtaining     patent  and <font color="blue"><font color="blue">trade secret</font> protection</font> for new <font color="blue">technologies</font>, products and     processes</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, on our ability, and the ability     of our <font color="blue">licensors</font>, to obtain and to keep protection for our products and     <font color="blue">technologies</font> under the <font color="blue">patent laws</font> of the <font color="blue">United States</font> and other countries,     so that                                           21     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>we can <font color="blue">stop others from using</font> our <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success also will depend</font>     on our ability to <font color="blue">prevent others from using</font> our <font color="blue"><font color="blue">trade secret</font>s</font></td>
    </tr>
    <tr>
      <td>In addition,     we must operate in a way that does not infringe, or violate, the patent,     <font color="blue">trade secret</font> and other <font color="blue"><font color="blue">intellectual</font> property rights</font> of other parties</td>
    </tr>
    <tr>
      <td>We cannot know how much protection, if any, our <font color="blue">patents will provide</font> or     whether our patent <font color="blue">application</font>s will issue as patents</td>
    </tr>
    <tr>
      <td>The breadth of claims     that will be allowed in patent <font color="blue">application</font>s cannot be predicted and neither     the <font color="blue">validity nor enforceability</font> of claims in <font color="blue"><font color="blue">issued patent</font>s</font> can be assured</td>
    </tr>
    <tr>
      <td>If,  for  any reason, we are unable to obtain and enforce valid claims     covering  our  products  and  <font color="blue">technology</font>,  we may be unable to prevent     <font color="blue">competitors</font>  from  using  the same or similar <font color="blue">technology</font> or to prevent     <font color="blue">competitors</font> from marketing identical products</td>
    </tr>
    <tr>
      <td>In addition, due to the     extensive time needed to develop and test our products, any patents that we     obtain may expire in a short time after <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>This would reduce     or  eliminate any <font color="blue">advantages</font> that <font color="blue">such patents may give us</font></td>
    </tr>
    <tr>
      <td>In certain     <font color="blue">territories</font>  outside  the  US,  our <font color="blue"><font color="blue">issued patent</font>s</font> may be subject to     <font color="blue">opposition by</font> <font color="blue">competitors</font> within a certain time after the patent is issued</td>
    </tr>
    <tr>
      <td>Such is the case with our MT 400 patent in Europe, which is subject to     <font color="blue">opposition by</font> <font color="blue">Merck and Almirall Prodesfarma</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">opposition proceedings</font>     may not resolved for <font color="blue">several years</font>, and may result in the revocation of the     <font color="blue">issued patent</font></td>
    </tr>
    <tr>
      <td>In certain <font color="blue">territories</font> outside the US, our <font color="blue"><font color="blue">issued patent</font>s</font> may be subject     to <font color="blue">opposition by</font> <font color="blue">competitors</font> within a certain time after the patent is     issued</td>
    </tr>
    <tr>
      <td>For example, in October 2005 oppositions were <font color="blue">filed against</font> our     issued  <font color="blue">European  </font>patent  for MT 400 by Merck &amp; Co, Inc</td>
    </tr>
    <tr>
      <td>and Almirall     Prodesfarma asserting that the European <font color="blue">patent should</font> not have <font color="blue">been granted</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">opposition proceedings</font> may not be resolved for <font color="blue">several years</font>, and may     result in the revocation of the <font color="blue">issued patent</font></td>
    </tr>
    <tr>
      <td>We may need to submit our <font color="blue"><font color="blue">issued patent</font>s</font> for <font color="blue">amendment</font> or reissue if we     determine that any claims within our <font color="blue">patents should</font> not have <font color="blue">been issued</font></td>
    </tr>
    <tr>
      <td>While such a <font color="blue">submission may</font> be <font color="blue">based on</font> our view that <font color="blue">only specified</font> claims     should not have <font color="blue">been granted</font> to us, there can be no assurance that a patent     <font color="blue">examiner will</font> not determine that <font color="blue">additional</font> claims should not have been     granted to us</td>
    </tr>
    <tr>
      <td>Such a risk exists with one of our patents covering MT 100,     which we submitted for reissue after determining that <font color="blue">certain specified</font>     claims that are not central to our protection of MT 100 should not have been     issued</td>
    </tr>
    <tr>
      <td>We  may need to <font color="blue">license rights</font> to <font color="blue"><font color="blue">third party</font> patents</font> and <font color="blue">intellectual</font>     property  to  continue  the  <font color="blue">development</font>  and marketing of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we are unable to acquire <font color="blue">such rights on</font> acceptable terms, our     <font color="blue">development</font> <font color="blue">activities</font> may be blocked and we may be unable to bring our     <font color="blue">product <font color="blue">candidates</font></font> to market</td>
    </tr>
    <tr>
      <td>We  may  enter  into  <font color="blue">litigation</font> to <font color="blue">defend ourselves against</font> claims of     <font color="blue">infringement</font>, assert claims that a <font color="blue">third party</font> is <font color="blue">infringing one</font> or more of     our patents, protect our <font color="blue"><font color="blue">trade secret</font>s</font> or know-how, or determine the scope     and validity of others’ patent or <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>As a result of such     <font color="blue">litigation</font>, our patent claims may be found to be invalid, unenforceable or     not of sufficient scope to cover the <font color="blue">activities</font> of an alleged <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>With respect to some of our <font color="blue">product <font color="blue">candidates</font></font>, under certain <font color="blue">circumstances</font>,     our <font color="blue">development</font> or <font color="blue">commercialization</font> <font color="blue"><font color="blue">collaborator</font>s</font> have the first right to     enforce our patents and would have exclusive <font color="blue">control over</font> such <font color="blue">enforcement</font>     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>For example, under our <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font> with</font> GSK, GSK has     the first right to enforce our patents</td>
    </tr>
    <tr>
      <td>If we are found to infringe the <font color="blue">patent rights</font> of others, then we may be     forced to pay damages in an amount that <font color="blue">might irreparably harm</font> our business     and/or be <font color="blue">prevented from continuing</font> our product <font color="blue">development</font> and marketing     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Additionally, if we or our <font color="blue">development</font> or <font color="blue">commercialization</font>     <font color="blue">collaborator</font> seek to enforce our patents and are <font color="blue">unsuccessful</font>, we may be     subject to claims for bringing a failed <font color="blue">enforcement</font> action, including claims     alleging <font color="blue">various forms</font> of antitrust violations (both state and federal) and     unfair <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>If we are found to be liable for such claims, then we     may be forced to pay damages in an amount that <font color="blue">might irreparably harm</font> our     business and/or be <font color="blue">prevented from continuing</font> our product <font color="blue">development</font> and     <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Even if we are successful in defending any     such claims of <font color="blue">infringement</font> or in asserting claims against <font color="blue">third parties</font>,     such <font color="blue">litigation</font> is expensive, may have a material effect on our <font color="blue">operations</font>,     and may distract <font color="blue">management</font> from our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of its     eventual  outcome, any lawsuit that we <font color="blue">enter into</font> may consume time and     resources that would impair our ability to develop and market our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We  have  entered  into confidentiality <font color="blue"><font color="blue">agreement</font>s</font> with our employees,     consultants, advisors and <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">parties may</font> not     honor these <font color="blue"><font color="blue">agreement</font>s</font> and, as a result, we may not be able to protect our     rights to unpatented <font color="blue"><font color="blue">trade secret</font>s</font> and know-how</td>
    </tr>
    <tr>
      <td>Others <font color="blue">may independently</font>     develop <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font> information and <font color="blue">techniques</font> or     <font color="blue">otherwise gain access</font> to our <font color="blue"><font color="blue">trade secret</font>s</font> and know-how</td>
    </tr>
    <tr>
      <td>Also, many of our     scientific and <font color="blue">management</font> personnel were <font color="blue">previously</font> employed by competing     companies</td>
    </tr>
    <tr>
      <td>If we fail to acquire, develop and <font color="blue">commercialize</font> <font color="blue">additional</font> products or     <font color="blue">product <font color="blue">candidates</font></font>, or fail to <font color="blue"><font color="blue">successfully</font> promote</font> or <font color="blue">market approved</font>     products, we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As part of our business strategy, we plan to identify, self-invent and/or     acquire <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">approved products</font> in areas in which we possess     <font color="blue">particular knowledge</font></td>
    </tr>
    <tr>
      <td>Because we do not directly engage in <font color="blue">basic research</font> or     drug <font color="blue">discovery</font>, we may rely upon <font color="blue">third parties</font> to sell or <font color="blue">license product</font>     <font color="blue">opportunities</font> to us</td>
    </tr>
    <tr>
      <td>Other companies, including some with <font color="blue">substantially</font>     greater financial, marketing and <font color="blue">sales resources</font>, are <font color="blue">competing with us</font> to     acquire <font color="blue">such products</font> and <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may not be able to acquire     rights to <font color="blue">additional</font> products or <font color="blue">product <font color="blue">candidates</font></font> on acceptable terms, if     at all</td>
    </tr>
    <tr>
      <td><font color="blue">In                                           </font>22     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>addition, if we acquire <font color="blue">new products</font> or <font color="blue">product <font color="blue">candidates</font></font> with <font color="blue">different</font>     marketing strategies, <font color="blue">distribution</font> channels and bases of <font color="blue">competition</font> than     those of our current <font color="blue">product <font color="blue">candidates</font></font>, we may not be able to compete     favorably in those <font color="blue">product categories</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">product <font color="blue">candidates</font></font> perform <font color="blue">successfully</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> and     are  approved  by the FDA and other <font color="blue">regulatory</font> authorities, our future     <font color="blue">products may</font> not achieve <font color="blue">market acceptance</font> and may not generate the revenues     that we anticipate</td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market acceptance</font> will depend upon a     number of factors, including:           •   the receipt and timing of <font color="blue"><font color="blue">regulatory</font> approval</font>s;           •   the <font color="blue">availability</font> of third-party reimbursement;           •   the <font color="blue">indication</font>s for which the product is approved;           •   the rate of <font color="blue">adoption by healthcare providers</font>;           •   the rate of <font color="blue">product acceptance by target patient populations</font>;           •   the price of the <font color="blue">product relative</font> to <font color="blue">alternative</font> therapies;           •   the <font color="blue">availability</font> of <font color="blue">alternative</font> therapies;           •   the extent and <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">marketing efforts by us</font> and     third-party distributors and agents;           •   the existence of <font color="blue">adverse publicity</font> regarding our products or similar     products; and           •   the extent and severity of side <font color="blue">effects as compared</font> to <font color="blue">alternative</font>     therapies</td>
    </tr>
    <tr>
      <td>If we do not receive adequate third-party reimbursements for our future     products, our revenues and <font color="blue"><font color="blue">profitability</font> will</font> be reduced</td>
    </tr>
    <tr>
      <td>Our  ability to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">successfully</font> will     depend, in part, on the extent to <font color="blue">which reimbursement</font> for the costs of such     products and related <font color="blue">treatments will</font> be available from <font color="blue">government</font> health     administration authorities, such as Medicare and Medicaid in the US,     <font color="blue">private health insurers</font> and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font>     exists  as  to the <font color="blue">reimbursement status</font> of a <font color="blue">newly approved healthcare</font>     product</td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party coverage may not be available to <font color="blue">enable us</font> to     maintain <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate return on</font> our     <font color="blue">investment</font> in <font color="blue">product research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate coverage</font> and     <font color="blue">reimbursement levels</font> are not provided by <font color="blue">government</font> and third-party payors     for use of our products, our <font color="blue">products may</font> fail to achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>Our future revenues, <font color="blue">profitability</font> and access to <font color="blue">capital will</font> be <font color="blue">affected by</font>     the <font color="blue">continuing efforts</font> of <font color="blue">government</font>al and private third-party payors to     contain or reduce the costs of <font color="blue">healthcare through various</font> means</td>
    </tr>
    <tr>
      <td>We expect     that a number of federal, state and <font color="blue">foreign proposals will seek</font> to control     the cost of drugs through <font color="blue">government</font>al regulation</td>
    </tr>
    <tr>
      <td>We are unsure of the form     that any <font color="blue">healthcare reform legislation may</font> take or what <font color="blue">actions federal</font>,     state, foreign and <font color="blue">private payors may</font> take in response to any proposed     reforms</td>
    </tr>
    <tr>
      <td>Therefore, we <font color="blue">cannot predict</font> the effect of any <font color="blue">implemented reform</font>     on our business</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">product <font color="blue">liability</font></font> lawsuits</font> are <font color="blue">successfully</font> <font color="blue">brought against</font> us, we may     incur substantial <font color="blue">liabilities</font> and may be required to limit <font color="blue">commercialization</font>     of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The testing and marketing of <font color="blue">pharmaceutical products</font> entails an inherent     risk of <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims might be <font color="blue">brought against</font>     us by consumers, healthcare providers, <font color="blue">pharmaceutical companies</font> or others     selling our <font color="blue">future product</font>s</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> defend ourselves     <font color="blue">against such</font> claims, we may incur substantial <font color="blue">liabilities</font> or be required to     limit the <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have product     <font color="blue">liability</font> insurance that covers our human <font color="blue"><font color="blue">clinical trial</font>s</font> in an amount equal     to up to dlra10dtta0 million annual aggregate limit with a dlra0dtta1 million deductible     per  claim</td>
    </tr>
    <tr>
      <td>The amount of insurance that we currently hold may not be     adequate  to  cover all <font color="blue">liabilities</font> that may occur</td>
    </tr>
    <tr>
      <td>However, insurance     coverage is becoming increasingly expensive, and no assurance can be given     that we will be able to maintain <font color="blue"><font color="blue">insurance coverage</font> at</font> a <font color="blue">reasonable cost</font> or     in <font color="blue">sufficient amounts</font> to <font color="blue">protect us against losses due</font> to <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We     intend to expand our <font color="blue">insurance coverage</font> to include the sale of commercial     products if we obtain <font color="blue">marketing approval</font> for any of our products</td>
    </tr>
    <tr>
      <td>However,     we may not be able to obtain commercially reasonable <font color="blue">product <font color="blue">liability</font></font>     insurance for any <font color="blue">products approved</font> for marketing</td>
    </tr>
    <tr>
      <td>If a plaintiff brings a     successful <font color="blue">product <font color="blue">liability</font></font> claim against us in excess of our insurance     coverage, if any, we may incur substantial <font color="blue">liabilities</font> and our business may     be harmed or fail</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>We may need <font color="blue">additional</font> funding and may not have access to capital</td>
    </tr>
    <tr>
      <td>If we are     unable  to  <font color="blue">raise capital</font> when needed, we may need to delay, reduce or     eliminate our product <font color="blue">development</font> or <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>We may need to raise <font color="blue">additional</font> funds to execute our business strategy</td>
    </tr>
    <tr>
      <td>We     have <font color="blue">incurred losses</font> from <font color="blue">operations</font> since inception and we <font color="blue">may continue</font> to     incur <font color="blue">additional</font> operating losses</td>
    </tr>
    <tr>
      <td>Our actual capital <font color="blue"><font color="blue">requirement</font>s</font> will     <font color="blue">depend upon numerous factors</font>, including:           •   the progress of our research and <font color="blue">development</font> programs;           •   the progress of preclinical studies, clinical and other testing or the     need conduct <font color="blue">additional</font> trials, studies or other testing;           •   the time and <font color="blue">cost involved</font> in obtaining any <font color="blue"><font color="blue">regulatory</font> approval</font>s;           •   the costs of filing, prosecuting, defending and enforcing any patent     claims and other <font color="blue"><font color="blue">intellectual</font> property rights</font>;           •   the effect of <font color="blue">competing technological</font> and market <font color="blue">development</font>s;           •   the timing of our receipt, if any, of <font color="blue">milestone payments</font> and royalties     under <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font>;           •   the effect of changes and <font color="blue">development</font>s in, or <font color="blue">termination</font> of, our     <font color="blue">collaborative</font>, license and other <font color="blue">relationships</font>;           •   the terms and timing of any <font color="blue">additional</font> <font color="blue">collaborative</font>, license and     other <font color="blue"><font color="blue">arrangement</font>s</font> that we <font color="blue">may establish</font>; and           •   our ability to arrange for the <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> may require us to <font color="blue">grant product</font>     <font color="blue">development</font> programs or licenses to <font color="blue">third parties</font> for products that we might     <font color="blue">otherwise seek</font> to develop or <font color="blue">commercialize</font> ourselves which may increase our     capital <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">fiscal year</font>s 2003 through 2005, our <font color="blue">average annual</font> operating expenses     (including average non-cash deferred compensation of dlra0dtta6 million) were     dlra25dtta4 million</td>
    </tr>
    <tr>
      <td>We are currently expecting operating expenses for the 2006     <font color="blue">fiscal year</font> to be between dlra32dtta0 million and dlra36dtta0 million, excluding any     non-cash compensation expense that would result from the award of stock     <font color="blue">options upon</font> the adoption of SFAS 123(R)</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had     dlra45dtta8 million in cash and <font color="blue">cash equivalents</font> and short-term <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>If     our operating expenses in 2006 and 2007 are at the level of our currently     expected operating expenses for 2006 and if we do not receive any <font color="blue">additional</font>     <font color="blue">milestone payments</font> under any of our <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font>, we will not     have <font color="blue">sufficient cash reserves</font> to maintain our level of business <font color="blue">activities</font>     throughout 2007</td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">expenses might increase</font> in 2006 and 2007     <font color="blue">beyond currently</font> expected levels if any <font color="blue">regulatory</font> agency requires us to     conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>, studies or <font color="blue">investigations</font>, including in     <font color="blue">connection with</font> their <font color="blue">consideration</font>, or re<font color="blue">consideration</font>, of our <font color="blue">regulatory</font>     filings for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, we may be required to pay     <font color="blue">Valeant NA </font>a <font color="blue">withdrawal fee</font> of dlra1dtta0 million if we do not prevail in our     current dispute with them as to whether the <font color="blue">withdrawal fee</font> is payable under     our MT 300 <font color="blue">collaboration</font> <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We may be unable to raise <font color="blue">additional</font> equity funds when we desire to do so     due to unfavorable market <font color="blue">conditions</font> in our industry or <font color="blue">generally</font>, or other     unforeseen <font color="blue">development</font>s in our business</td>
    </tr>
    <tr>
      <td>Further, we may not be able to find     <font color="blue">sufficient debt</font> or <font color="blue">equity funding</font>, if at all, on acceptable terms</td>
    </tr>
    <tr>
      <td>If we     cannot, we may need to delay, reduce or <font color="blue">eliminate research</font> and <font color="blue">development</font>     programs and <font color="blue">therefore may</font> not be able to execute our business strategy</td>
    </tr>
    <tr>
      <td>The <font color="blue">sale by us</font> of <font color="blue">additional</font> equity securities or the <font color="blue">expectation</font> that we     will sell <font color="blue">additional</font> equity securities may have an adverse effect on the     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on key personnel</font> and may not be able to retain these employees or     recruit <font color="blue">additional</font> qualified personnel, which would harm our research and     <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent on</font> the efforts of our key <font color="blue">management</font> and scientific     personnel, especially John R Plachetka, Pharm</td>
    </tr>
    <tr>
      <td><font color="blue">Plachetka </font>signed an employment <font color="blue">agreement</font>     <font color="blue">with us on</font> April 1, 1999, as amended and <font color="blue">restated on</font> July 25, 2001, for a     three-year term with automatic one-year renewal terms</td>
    </tr>
    <tr>
      <td>We <font color="blue">also entered into</font>     employment <font color="blue"><font color="blue">agreement</font>s</font> with certain of our other key <font color="blue">management</font> personnel,     <font color="blue">which provide</font> for one or two-year terms with automatic one-year renewal     terms</td>
    </tr>
    <tr>
      <td>If we <font color="blue">should lose</font> the services of Dr</td>
    </tr>
    <tr>
      <td>Plachetka, or are unable to     replace the services of our other key personnel who may leave the Company,     such  as  Dr</td>
    </tr>
    <tr>
      <td>W James Alexander, Senior Vice     President,  Product  Development,  or  if we fail to recruit other key     scientific personnel, we may be unable to achieve our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>There is intense <font color="blue">competition</font> for <font color="blue">qualified scientific personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to continue to attract and retain the     qualified personnel <font color="blue">necessary</font> for developing our business</td>
    </tr>
    <tr>
      <td>Furthermore, our     <font color="blue">future success may also depend</font> in part on the <font color="blue">continued service</font> of our other     key <font color="blue">management</font> personnel and our ability to recruit and retain <font color="blue">additional</font>     personnel, as required by our business</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font>Factors That May Affect Our Stockholders        Our stock price is volatile, which may result in <font color="blue"><font color="blue">significant</font> losses</font> to     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>There has <font color="blue">been <font color="blue">significant</font> volatility</font> in the <font color="blue"><font color="blue">market price</font>s</font> of bio<font color="blue">technology</font>     companies’ securities</td>
    </tr>
    <tr>
      <td>Various factors and <font color="blue">events may</font> have a <font color="blue">significant</font>     <font color="blue">impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These factors include:           •   <font color="blue">fluctuations</font> in our operating results;           •   <font color="blue">announcements</font> of technological innovations, <font color="blue">acquisition</font>s or licensing     of therapeutic products or <font color="blue">product <font color="blue">candidates</font></font> by us or our <font color="blue">competitors</font>;           •   published reports <font color="blue">by securities analysts</font>;           •   positive or negative progress with our <font color="blue"><font color="blue">clinical trial</font>s</font> or with     <font color="blue"><font color="blue">regulatory</font> approval</font>s of our <font color="blue">product <font color="blue">candidates</font></font>;           •   <font color="blue">government</font>al regulation, including <font color="blue">reimbursement policies</font>;           •   <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights;           •   <font color="blue">development</font>s in our <font color="blue">relationships</font> with <font color="blue">collaborative</font> partners;           •   <font color="blue">development</font>s in new or pending <font color="blue">litigation</font>;           •   public concern as to the safety and efficacy of our products; and           •   general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> has been, and <font color="blue">could continue</font> to be,     subject to wide <font color="blue">fluctuations</font> in response to these factors, including the     sale  or <font color="blue">attempted sale</font> of a large amount of our <font color="blue">common stock</font> into the     market</td>
    </tr>
    <tr>
      <td><font color="blue">From October </font>16, 2000, when our <font color="blue">common stock</font> began trading on the     Nasdaq National Market, through March 1, 2006, the high and low closing     prices  of  our <font color="blue">common stock</font> ranged from dlra2dtta25 to dlra21dtta75</td>
    </tr>
    <tr>
      <td>Broad market     <font color="blue">fluctuations</font> may also <font color="blue">adversely affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Sales of substantial amounts of our <font color="blue">common stock</font> in the <font color="blue"><font color="blue">public market</font> could</font>     depress our stock price</td>
    </tr>
    <tr>
      <td>We have not sold shares of <font color="blue">common stock</font> in a <font color="blue">public offering since</font> our     <font color="blue">initial public offering</font> in October 2000</td>
    </tr>
    <tr>
      <td>Accordingly, we have a <font color="blue">relatively</font>     small  number  of shares that are traded in the market and four of our     <font color="blue">stockholders</font> and their <font color="blue">affiliates beneficially</font> hold approximately 34prca of our     <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>Any sales of substantial amounts of our <font color="blue">common stock</font> in     the <font color="blue">public market</font>, including sales or <font color="blue">distribution</font>s of <font color="blue">shares by</font> our large     <font color="blue">stockholders</font>, or the <font color="blue">perception</font> that <font color="blue">such sales might</font> occur, <font color="blue">could harm</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font> and <font color="blue">could impair</font> our ability to raise     capital  through  the  sale  of <font color="blue">additional</font> equity securities</td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">stockholders</font>’ ownership will be diluted if we raise <font color="blue">additional</font> capital by     <font color="blue">issuing equity securities</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">filed with</font> the SEC, and the SEC has     declared <font color="blue">effective</font>, a <font color="blue">shelf registration statement on</font> Form S-3 under which     we <font color="blue">may register up</font> to 8cmam540cmam000 shares of our <font color="blue">common stock</font> for sale to the     public in one or more <font color="blue">public offerings</font></td>
    </tr>
    <tr>
      <td>Certain selling <font color="blue">stockholders</font> named     in the prospectus for the <font color="blue">registration statement may offer up</font> to 540cmam000 of     such shares, and we would not receive any of the <font color="blue">proceeds from sales</font> of     those shares</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">charter documents</font> and under <font color="blue">Delaware </font>law     <font color="blue">could prevent</font> or <font color="blue">delay <font color="blue">transactions</font></font> that our <font color="blue">stockholders</font> may favor and may     prevent <font color="blue">stockholders</font> from changing the direction of our business or our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our charter and bylaws may discourage, delay or prevent a     merger  or  <font color="blue">acquisition</font>  that our <font color="blue">stockholders</font> may consider favorable,     including <font color="blue">transactions</font> in which you might otherwise receive a premium for     your shares, and may also frustrate or prevent any attempt by <font color="blue">stockholders</font>     to  change  the  direction  or <font color="blue">management</font> <font color="blue">of POZEN For </font>example, these     provisions:           •   authorize the issuance of “blank check” preferred stock without any     need for action by <font color="blue">stockholders</font>;           •   provide for a <font color="blue">classified board</font> of <font color="blue">directors</font> with staggered three-year     terms;           •   require <font color="blue">supermajority stockholder approval</font> to effect various     <font color="blue">amendment</font>s to our charter and bylaws;           •   eliminate the ability of <font color="blue">stockholders</font> to <font color="blue">call special meetings</font> of     <font color="blue">stockholders</font>;           •   <font color="blue">prohibit stockholder action by written consent</font>; and           •   <font color="blue">establish advance</font> notice <font color="blue"><font color="blue">requirement</font>s</font> for <font color="blue">nominations</font> for election to     the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be acted on by     <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [55]Table of <font color="blue">Contents       </font>Further, in January 2005 our board of <font color="blue">directors</font> adopted a <font color="blue">stockholder rights</font>     plan, similar to plans <font color="blue">adopted by</font> many other publicly-traded companies</td>
    </tr>
    <tr>
      <td>The     <font color="blue">stockholder rights</font> plan is intended to deter an attempt to acquire us in a     manner or on terms not <font color="blue">approved by</font> our board of <font color="blue">directors</font></td>
    </tr>
  </tbody>
</table>